<?xml version="1.0" encoding="UTF-8"?>
<p>The hydroxychloroquine has shown a potent efficacy in treating patients with COVID-19 pneumonia. More than hundred patients showed the superiority of chloroquine compared with treatment of standard care in terms of reduction of exacerbation of pneumonia, viral load and symptoms (Chinese Clinical Trial Registry, n.d.; Gao et al., 
 <xref rid="CIT0015" ref-type="bibr">2020</xref>). Colson group have suggested that chloroquine and hydroxychloroquine as available weapons to fight COVID-19 (Colson et al., 
 <xref rid="CIT0012" ref-type="bibr">2020</xref>). In 2014-2017, ivermectin antiviral drug used for phase 3 treatment of dengue infection, daily oral dose significantly reduced in serum level of viral NS1 protein. Caly et al. (
 <xref rid="CIT0007" ref-type="bibr">2020</xref>) have demonstrated Ivermectin-treatment can reduce ∼5000-fold viral RNA load compared to the control sample in cell cultural at 48 h, but no further reduction observed at 72 h.
</p>
